US Corporate Distress Financial Stress SEC Filings — April 06, 2026

06-04-2026

Profusa, Inc. entered into a non-binding Letter of Intent (LOI), dated March 31, 2026, as amended April 4, 2026, to acquire Bio Insights LLC's PanOmics assets for $30 million in stock, including 460,000 common shares at closing (capped at 19.99% of outstanding shares) and preferred stock convertible into 59,540,000 common shares after one year. The deal includes plans for $10 million in additional equity financing, allocation of up to $2 million for PanOmics validation, 3% net revenue royalties to Bio Insights, and board nomination rights, but remains subject to due diligence, definitive agreements by May 1, 2026, and shareholder approval before June 30, 2026.

• ·LOI terminates automatically on May 1, 2026, unless extended or definitive agreements executed.
• ·Exclusivity period prevents Bio Insights from engaging with other parties on similar transactions.
• ·Lock-up on conversion shares for 7 years with annual 1/7th releases and tax liability carve-out.
• ·Samples: Cohort 1 ([***] samples) within 5 business days post-closing; Cohort 2 ([***] samples) within 30 days post-MTA.

06-04-2026

Neurocrine Biosciences (NBIX) has agreed to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash, representing a total equity value of $2.9 billion and premiums of 34% to the April 2, 2026 closing price and 51% to the 30-day VWAP. The deal adds VYKAT XR (diazoxide choline), which generated $190 million in 2025 revenue ($92 million in Q4), to Neurocrine's portfolio of first-in-class therapies including INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), strengthening its endocrinology and rare disease presence with IP extending into the mid-2040s. The transaction, funded by cash and modest debt without a financing condition, is expected to close within 90 days subject to regulatory approvals and customary conditions.

• ·PWS occurs in one in every 15,000 live births per Prader-Willi Syndrome Association USA.
• ·VYKAT XR approved by FDA in March 2025; CRENESSITY approved in December 2024.
• ·Neurocrine to host conference call at 8:00 AM ET on April 6, 2026.
• ·Advisors: Goldman Sachs & Co. LLC (financial, Neurocrine), Cooley LLP (legal, Neurocrine), Centerview Partners LLC and Guggenheim Securities, LLC (financial, Soleno), Wilson Sonsini Goodrich & Rosati (legal, Soleno).

06-04-2026

Goldman Sachs Real Estate Finance Trust Inc disclosed entry into a material indenture dated March 31, 2026, among GS REFT 2026-FL1 Issuer, Ltd., GS REFT 2026-FL1 Co-Issuer, LLC, GS REFT CLO Seller, LLC (as Advancing Agent), Wilmington Trust, National Association (as Trustee), and Computershare Trust Company, National Association (as Note Administrator), governing the issuance of Offered Notes secured by Collateral including Closing Date Collateral Interests, Subsequent Collateral Interests, Delayed Close Collateral Interest, Servicing Accounts, and related rights. The transaction establishes standard provisions for note issuance, collateral management, payments, remedies, and covenants without specific issuance amounts or performance metrics disclosed. No period-over-period comparisons or financial impacts are detailed.

• ·Indenture effective as of March 31, 2026; SEC 8-K filed April 06, 2026 under Items 1.01, 2.03, 9.01
• ·Collateral excludes Excepted Property and any Retained Interest under Collateral Interest Purchase Agreement
• ·Notes issuable in forms including Regulation S Global Note, Rule 144A Global Note, and Definitive Notes

06-04-2026

Westlake Corporation entered into a new Credit Agreement dated April 2, 2026, with JPMorgan Chase Bank, N.A. as Administrative Agent and a syndicate of lenders including joint bookrunners BofA Securities, Inc., Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc. The facility supports revolving borrowings and letters of credit in Agreed Currencies, with an Alternate Currency Sublimit of $1.5 billion and pricing at Level III based on public debt ratings (equivalent to BBB/Baa2/BBB). No performance declines or comparisons are disclosed in the filing.

• ·Filing date: April 6, 2026
• ·Current Applicable Rate at Pricing Level III: Term Benchmark Loans 125.0 bps, RFR Loans 125.0 bps, ABR Loans 25.0 bps, Undrawn Commitment Fee 12.5 bps
• ·Alternate Currencies include Euros and Pounds Sterling
• ·Agreed Currencies: U.S. Dollars and Alternate Currencies

06-04-2026

The Honest Company, Inc. entered into the First Amendment to its Credit Agreement and Pledge and Security Agreement, both originally dated January 25, 2023, as of March 31, 2026, subject to conditions precedent including executed documents, legal opinions, secretary certificates, and representations of no Default or Event of Default. The amendments update specific sections, schedules, exhibits, and render Section 2 of the Fee Letter inapplicable, while ratifying the existing loan documents without waiving any rights or remedies. No quantitative changes to facility terms are disclosed in the filing.

• ·Amendment filed as 8-K on April 06, 2026 (Items 1.01, 1.02, 2.03, 9.01).
• ·Governed by laws of the State of California.
• ·Executed in counterparts with electronic signatures permitted.

06-04-2026

Greenpro Capital Corp. consummated a Share Exchange Agreement on March 31, 2026, acquiring 1,360 ordinary shares of Forekast Limited (13.6% of its outstanding equity on a fully diluted basis) in exchange for issuing 8,500,000 shares of its common stock to Forekast shareholders. This nearly doubled outstanding shares from 8,625,813 to 17,125,813, significantly diluting existing ownership, with directors and officers' collective stake dropping from 39.67% to 19.98% and principal shareholders now holding 52.88%. The transaction was a minority investment without gaining control of Forekast.

• ·BHL Ltd. received 3,250,000 Company shares for 520 Forekast shares (previously 5.2% Forekast owner).
• ·Moira Venture Limited, Renhari Limited, Joharne Limited, Crescent East Limited, and Stratifi Global Limited each received 1,125,000 Company shares for 180 Forekast shares (previously 1.8% each).
• ·Exchange Shares issued under Rule 506 of Regulation D as restricted securities.

06-04-2026

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced a proposed underwritten public offering of shares of its common stock and accompanying Series A and Series B warrants (or pre-funded warrants in lieu thereof), all to be sold by the company. Piper Sandler is acting as sole manager, with INOVIO intending to grant a 30-day underwriter option to purchase up to 15% additional securities under the same terms. The offering is subject to market conditions, with no assurance of completion, size, or terms, and will be made via a prospectus supplement to a previously effective shelf registration.

• ·Shelf registration statement filed with SEC on November 9, 2023, and declared effective on January 31, 2024.
• ·Prospectus available via Piper Sandler at (800) 747-3924 or prospectus@psc.com.
• ·INOVIO focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases.

06-04-2026

Neurocrine Biosciences has entered a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion, a 34% premium to Soleno's April 2, 2026 closing price and 51% to its 30-day VWAP. The deal adds VYKAT XR, which generated $190 million in 2025 revenue including $92 million in Q4, to Neurocrine's portfolio alongside INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), supported by IP extending into the mid-2040s. The transaction is expected to close within 90 days, subject to customary conditions including regulatory approvals.

• ·VYKAT XR FDA approved March 2025, launched Q2 2025; CRENESSITY approved December 2024
• ·Transaction funded by cash on hand and modest pre-payable debt; not subject to financing condition
• ·Neurocrine conference call at 8:00 AM ET on April 6, 2026
• ·VYKAT XR IP estate expected to extend into mid-2040s

06-04-2026

On April 1, 2026, subsidiaries Trinity Industries Leasing Company (TILC) and Trinity Rail Leasing 2025 LLC (TRL-2025) of Trinity Industries, Inc. entered a Note Purchase Agreement with initial purchasers including ATLAS SP Securities, BofA Securities, Inc., and others for the issuance of $447,439,000 in Series 2026-1 Class A Secured Green Standard Railcar Notes at 5.35% interest and $33,360,000 in Class B Notes at 5.56% interest, both with monthly payments and maturity on April 19, 2056. The notes are secured by approximately 15,082 railcars and related leases, as part of an asset-backed securitization expected to close on or about April 17, 2026, subject to customary conditions. There are no period-over-period comparisons or performance metrics reported.

• ·Class A Notes bear fixed interest at 5.35%, payable monthly.
• ·Class B Notes bear fixed interest at 5.56%, payable monthly.
• ·Notes to be resold pursuant to Rule 144A and Regulation S; not registered under Securities Act.
• ·Transaction subject to customary closing conditions; no assurance of closing on April 17, 2026 or at all.

06-04-2026

TAP Real Estate Technologies, Inc. entered into an Amendment to License Agreement with TAP, Inc. on March 31, 2026, extending the original agreement's term (entered December 30, 2025) from March 31, 2026, to June 30, 2026. The extension provides additional time to negotiate a final license agreement for certain technology. No financial terms or impacts are disclosed in the filing.

• ·Form 8-K filed on April 6, 2026, reporting event of March 31, 2026.
• ·Exhibit 10.1: Amendment to License Agreement dated March 31, 2026.

06-04-2026

On April 6, 2026, NioCorp Developments Ltd. held its Annual Meeting where shareholders approved the Amended and Restated Shareholder Rights Plan, extending its term to the 2027 annual meeting, and the 2017 Amended Long-Term Incentive Plan, authorizing up to 11,300,000 Common Shares for options, RSUs, and other awards, replacing the prior evergreen share limit. Shareholders also set the board at six directors, elected nominees (with significant withheld votes for some, e.g., 8.4M for Nilsa Guerrero-Mahon), appointed Deloitte & Touche LLP as auditors, and approved advisory say-on-pay, though several proposals saw notable opposition (e.g., 5.3M against LTIP amendment) amid 125,321,172 shares outstanding and only 56,773,600 present.

• ·Proposal One (Set directors at six): 55,164,407 For; 1,609,193 Against.
• ·Proposal Three (Appoint auditors): 55,986,839 For; 786,761 Withheld.
• ·Proposal Four (Say-on-pay advisory): 22,285,849 For; 6,272,537 Against; 397,390 Abstentions; 27,817,824 broker non-votes.
• ·Proposal Five (LTIP amendment): 23,285,354 For; 5,326,885 Against; 343,535 Abstentions; 27,817,826 broker non-votes.
• ·Proposal Six (Rights Plan amendment): 23,942,251 For; 4,719,596 Against; 293,931 Abstentions; 27,817,822 broker non-votes.
• ·Director elections broker non-votes ~27.8M each; withheld votes ranged 993,498 (Fulton) to 8,398,816 (Guerrero-Mahon).

06-04-2026

VRM MSP Recovery Partners LLC, managed by Virage Capital Management LP, provided a one-time $125,000 advance to MSP Recovery, LLC for accounts payables, with prior consents allowing use of recovery proceeds. Reimbursement is required immediately from proceeds of any new loans or financing (except short-term from Hazel Partners), including from YA II PN, Ltd. or debtor-in-possession financing, conditional on MSP Recovery appointing Nader Tavakoli as Chief Restructuring Officer. This signals ongoing financial strain and potential restructuring or Chapter 11 proceedings, with no obligation for further advances.

• ·Prior consents for recovery proceeds use via email (Sep 5, 2025) and letter agreements (Oct 16, 2025; Nov 14, 2025; Nov 26, 2025; Dec 19, 2025; Feb 19, 2026; advance agreement Mar 20, 2026)
• ·Reimbursement requires counterparty agreement to direct loan proceeds to repay advance and prior recovery proceeds
• ·Advance usage overseen by proposed Chief Restructuring Officer Nader Tavakoli

06-04-2026

Inogen, Inc. (Nasdaq: INGN) announced the appointment of Vafa Jamali, a seasoned medical device executive with prior leadership at ZimVie, Covidien, and Medtronic (including a $3 billion division), as an independent director to its Board, effective at the 2026 Annual Meeting or June 15, 2026, whichever is earlier. The appointment is accompanied by a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter, including standstill and voting provisions. Company leadership expressed optimism about Jamali's contributions to Inogen's transformation into a diversified respiratory care platform and ongoing growth initiatives.

• ·Cooperation agreement includes customary standstill, voting, and other provisions; to be filed as exhibit to Form 8-K
• ·Advisors: Evercore (financial), Covington & Burling LLP (legal), Joele Frank, Wilkinson Brimmer Katcher (strategic communications)

06-04-2026

Adapti, Inc. (ADTI) entered into an asset purchase agreement on April 1, 2026, acquiring substantially all assets of Levelution Sports Agency, LLC—including accounts receivable, athlete contracts, tangible property, intellectual property, prepaid expenses, and goodwill—in exchange for issuing 324,675 shares of its common stock. Of these, 32,468 shares are held in escrow for up to 18 months to cover potential indemnification obligations. Ancillary agreements include a 6-month transition services agreement with Kirk Noles at no additional cost and a 12-month lock-up on the shares.

• ·Shares issued in reliance on Section 4(a)(2) of the Securities Act and/or Regulation D exemption.
• ·Press release announcing the transaction issued on April 2, 2026.
• ·Transaction includes customary representations, warranties, covenants, and indemnifications.

06-04-2026

Hawkeye Systems, Inc. entered into a Note Purchase Agreement dated April 1, 2026, whereby Steve Hall sold an Existing Consolidated Promissory Note with $2,767,756 aggregate principal and interest due as of December 31, 2025 (original principal $1,770,713.10) to Hawkeye Holdco, LLC. Accrued interest from January 1, 2026, to the agreement date was extinguished. The Company amended and restated the note into a new $2,767,756 principal Convertible Promissory Note.

• ·Agreement governed by New York law with exclusive jurisdiction in New York courts.
• ·Transaction pursuant to Section 4(a)(2) of the Securities Act.

06-04-2026

Public Storage Operating Company (PSOC), a subsidiary of Public Storage, completed a $500 million offering of 5.000% Senior Notes due 2035 on April 6, 2026, guaranteed by Public Storage. The Notes bear interest at 5.000% per annum, payable semi-annually commencing June 15, 2026, and mature on December 15, 2035, with redemption options at a make-whole price or 100% of principal after September 15, 2035. The issuance is under an existing Indenture with covenants limiting indebtedness and requiring at least 125% unencumbered assets to unsecured debt.

• ·Notes are unsecured and unsubordinated, ranking equally with PSOC's existing and future similar indebtedness.
• ·Interest accrues from April 6, 2026; semi-annual payments on June 15 and December 15.
• ·Indenture includes customary events of default and limitations on mergers, consolidations, or asset sales.

06-04-2026

On April 3, 2026, Mativ Holdings, Inc. entered into the Ninth Amendment to its multicurrency credit agreement, refinancing existing facilities to provide a $305M revolving credit facility, $89.9M in Term A Loan commitments, and $500M in Term B Loan commitments, for a total of approximately $894.9M. The amendment eliminates the delayed draw term loan, adds subsidiaries as borrowers and guarantors, and sets interest margins based on Net Debt to EBITDA (1.75%-2.75% for revolver/Term A; 3.50%-4.50% for Term B). Maturities are tied to the 8.000% Senior Notes due 2029, with new covenants requiring minimum Interest Coverage Ratio starting at 2.50x (stepping up to 3.00x) and maximum Net Debt to EBITDA starting at 5.00x (stepping down to 4.00x).

• ·Three subsidiaries became additional U.S. Borrowers; another became a guarantor.
• ·Revolving and Term A Loans mature on earlier of 5-year anniversary of Amendment or 182 days prior to Senior Notes due 2029 maturity.
• ·Term B Loans mature on earlier of 7-year anniversary of Amendment or 91 days prior to Senior Notes due 2029 maturity.
• ·Commitment fee rate of 0.35% on revolving facility.

06-04-2026

New Era Energy & Digital, Inc. entered into an Amended and Restated Promissory Note dated April 6, 2026, with principal amount of $5,000,000 issued to Zachary Yi Zhou, which converts into shares of common stock at the Maturity Date. The Maturity Date is the earliest of September 30, 2026, closing of the TCDC Project Credit Facility, a Qualified Equity Financing raising $10,000,000 or more, or acceleration upon an Event of Default. Interest accrues at 5% per annum (or 18% upon default), payable in shares, with a potential MOIC Premium of up to 2% of the original principal upon full repayment.

• ·Conversion Price: Qualified Equity Financing Price Per Share, or average VWAP for 30 trading days prior to Maturity Date if no QEF.
• ·Events of Default include non-payment (5 Business Days cure for interest) or Bankruptcy Event, triggering acceleration and payment in shares.
• ·Governing law: State of Delaware; exclusive jurisdiction in Delaware courts.

06-04-2026

Greenlight Capital Re, Ltd. subsidiaries GRIL and Greenlight Re entered into Master Letter of Credit Agreements with CIBC Bank USA on April 1, 2026, establishing committed LC facilities totaling $300.0 million ($50.0 million for GRIL and $250.0 million for Greenlight Re), secured by cash collateral and maturing December 22, 2027. David Sigmon rescinded his February 2026 resignation notice on March 31, 2026, and will continue as General Counsel, Chief Compliance Officer, and Corporate Secretary.

• ·The Greenlight Re LC Agreement amends and restates the prior agreement dated December 22, 2023; the associated Credit Agreement from that date was terminated.
• ·Letters of credit issued for GRIL prior to April 1, 2026, were rolled over into the GRIL LC Facility.
• ·LC Facilities include customary conditions, representations, warranties, and events of default.

06-04-2026

Rain Enhancement Technologies Holdco, Inc. entered into an Amendment to its Loan Agreement with RHY Management LLC (controlled by Harry L. You) and Harry L. You personally, effective March 31, 2026, increasing the loan commitment from $7,000,000 to $10,000,000. This provides the Borrower with an additional $3,000,000 in financing capacity under the existing terms. No other amendments were made to the Loan Agreement.

• ·Original Loan Agreement dated December 30, 2024
• ·Amendment filed as part of 8-K on April 06, 2026, under Items 1.01, 2.03, 9.01
• ·Governed by New York law
• ·Executed in counterparts with electronic signatures accepted

06-04-2026

On March 31, 2026, certain holders of Nuvve Holding Corp.'s Series A Convertible Preferred Stock provided a waiver to the Certificate of Designation, agreeing to forgo rights to Alternate Consideration in the event of a Fundamental Transaction as defined in Section 7. This modification affects the rights of these preferred stockholders. The waiver is attached as Exhibit 10.1.

• ·Filing date: April 6, 2026
• ·Report date of earliest event: March 31, 2026
• ·Items reported: 3.03, 9.01

06-04-2026

Reborn Coffee, Inc. entered into a Forbearance Agreement with Arena Investors on March 31, 2026, waiving defaults and remedies related to a delay in paying 30% of the $6,500,000 gross cash proceeds from an October 20, 2025, equity issuance of 1,192,661 shares to Charles Joeng. In exchange, the Company committed to cash payments of $1,059,522 by April 6, 2026, $400,000 by April 20, 2026, and $500,000 monthly starting May 2026 until Debentures are repaid or converted, plus issuing warrants for 250,000 shares at $2.00 exercise price. This resolves the payment delay but imposes significant near-term cash outflows and potential shareholder dilution.

• ·Debentures originally issued to Arena Investors on February 10, 2025, February 26, 2025, March 28, 2025, and July 31, 2025.
• ·Arena Investors requested payment of 30% of October Agreement proceeds on February 19, 2026, leading to Specified Delay.
• ·Company to file registration statement covering Forbearance Warrants and other warrants issued December 31, 2025, within 5 business days of 10-K filing.

06-04-2026

Charles & Colvard Ltd, which filed for Chapter 11 bankruptcy on March 2, 2026, entered into a Section 364 DIP financing loan agreement with Van Lang Jewelry LLC on March 24, 2026, providing up to $1,000,000 for working capital, general corporate purposes, and bankruptcy costs, subject to an Approved Budget and strict milestones including an asset sale by July 7, 2026. The facility includes a $100,000 expense reserve for the lender and 9% interest, but features tight reporting requirements with 10% permitted variances and potential for default acceleration. This reflects ongoing financial distress with no immediate positive operational metrics.

• ·Petition Date: March 2, 2026; Closing Date: March 24, 2026; Filing Date: April 6, 2026.
• ·Milestones: Interim Order by March 24, 2026; Final Order by April 14, 2026; Asset Sale Motion by April 15, 2026; Asset Sale Procedures Order by April 30, 2026; Asset Sale Order by July 2, 2026; Asset Sale Effective Date by July 7, 2026.
• ·Reporting: Variance reports every other Wednesday starting April 8, 2026, for two-week Testing Periods.
• ·Mandatory prepayments: 100% of net cash proceeds from asset dispositions, insurance, condemnation, or non-ordinary course cash after prior liens.

06-04-2026

Neuronetics, Inc. (NASDAQ: STIM) announced the departure of Steven E. Pfanstiel as Executive Vice President, Chief Financial Officer, and Treasurer effective May 1, 2026, to pursue an external opportunity, with no disputes or disagreements; he will assist in an orderly transition. The company has launched a search for his replacement. Neuronetics reaffirmed its fiscal year 2026 financial guidance previously provided on its Q4 2025 earnings call on March 17, 2026.

• ·Filing items: 1.01, 2.05, 5.02, 7.01, 9.01
• ·Investor contact: Mike Vallie or Mark Klausner, ICR Healthcare (443-213-0499, ir@neuronetics.com)
• ·NeuroStar Advanced Therapy FDA-cleared for MDD in adults, OCD adjunct, anxious depression, and MDD in adolescents aged 15-21

06-04-2026

The Brink’s Company completed an amendment and extension of its credit facility on March 31, 2026, increasing it from $2.225 billion to $3.85 billion via a $1.025 billion delayed draw term loan and $600 million revolver increase, to fund the proposed acquisition of NCR Atleos Corporation, refinance its debt, and general purposes. The facility matures on March 31, 2031, at Term SOFR + 150 basis points. The acquisition remains subject to regulatory and shareholder approvals, with no guarantees of closing or realizing benefits.

• ·Pricing remains at Term SOFR + 150 basis points through acquisition consummation, subject to net leverage ratio.
• ·Strong interest from expanded bank group with significant oversubscription.
• ·Brink’s operates in 51 countries serving over 100 countries.

06-04-2026

Mawson Infrastructure Group Inc. entered a cooperation agreement with The Endeavor Investor Group, appointing three independent directors—Kyle B. Danges, K. Rodger Davis, and Lisa R. Hough—and two Endeavor affiliates, Cody Smith and Phillip Stanley, to its Board, effective immediately. Departing directors Ryan Costello (former Chair), Kathryn Schellenger, and Steven Soles stepped down as part of the agreement, which includes customary standstill provisions. The move is positioned as a step to reposition the business toward growth in digital infrastructure, including AI, HPC, and Bitcoin mining, with 129 megawatts of capacity already online.

• ·Cooperation agreement includes customary standstill provisions and will be filed as an exhibit to Form 8-K.
• ·Mawson focuses on carbon-free energy resources, including nuclear power, for its digital infrastructure.

06-04-2026

VistaOne DE SPV, L.P. entered into a Credit Agreement dated March 31, 2026, providing a revolving credit facility with Tranche A Commitments of $145,000,000 and Tranche B Commitments of $36,250,000. The facility supports portfolio investments with an Aggregate Eligible NAV Value of $1,459,898,744.81 as of the Closing Date. Goldman Sachs Bank USA serves as Administrative Agent, Calculation Agent, and a Lender, while The Bank of New York Mellon acts as Collateral Agent.

• ·Availability Period: Closing Date to February 28, 2029 (unless extended by Term-Out Conversations)
• ·Applicable Margin decreases to 3.00% if more than 30 unique Eligible Investments

06-04-2026

PacifiCorp entered into a $2,550,000,000 Letter of Credit Agreement dated April 3, 2026, with PNC Bank, National Association as Administrative Agent and PNC Capital Markets LLC as Lead Arranger, providing for the issuance of letters of credit by various Issuing Banks. The Aggregate Commitment is $2,550,000,000, with fees determined by an Applicable Percentage ranging from 0.875% to 1.750% based on PacifiCorp's S&P or Moody's ratings. No prior period data or performance declines are mentioned in the agreement.

• ·Applicable Percentage fees: 0.875% (Rating Level 1, A/A2 or higher) to 1.750% (Rating Level 6, BB+/Ba1 or below/unrated)
• ·Closing Date Aggregate Commitment: $2,550,000,000
• ·Agreement filed as Exhibit 10.1 in 8-K on April 6, 2026

06-04-2026

OFA Group's subsidiary, Office for Fine Architecture Limited, acquired a 50% undivided co-ownership interest in the QIKBIM system's intellectual property from Alan To AI Consultancy Co. Limited for an aggregate purchase price of $17,500,000. Historical payments of $11,994,800 were credited, with remaining obligations including a $2,998,700 final installment and $2,506,500 supplemental consideration due by December 31, 2026, plus a $880,000 escrow deposit credited against the supplemental amount. The Buyer gains sole control over operational, technical, strategic, and commercial matters for the QIKBIM business, with the Seller providing 24 months of transition support.

• ·Agreement effective March 31, 2026; Seller provides 24 months of transition support including bug fixes and knowledge transfer.
• ·Buyer has irrevocable option to acquire Seller's remaining interest upon specified events like breaches or insolvency.
• ·Net monetization proceeds shared 50/50 after Buyer recovers certain development costs; Buyer controls invoicing and collections.
• ·Late payments accrue 3% simple interest per annum; non-payment does not reverse IP assignment.

06-04-2026

McKesson Medical-Surgical Top Holdings Inc., a subsidiary of McKesson Corp, entered into a senior secured Credit Agreement dated April 1, 2026, providing $750.0 million in Closing Date Term A-1 Loans, $250.0 million in Closing Date Term A-2 Loans, and $1,000.0 million in Revolving Commitments. The proceeds will fund Transactions and general corporate purposes. JPMorgan Chase Bank, N.A. serves as Administrative Agent, Collateral Agent, Issuing Bank, and Swing Line Lender, with other major banks as Joint Lead Arrangers.

• ·Filing Date: April 06, 2026
• ·Agreement effective as of April 1, 2026

06-04-2026

Nexentis Technologies Inc. (formerly N2OFF, Inc. and Save Foods, Inc.), a company in the agriculture chemicals sector (SIC 2870), filed an 8-K on April 6, 2026, disclosing material modifications to the rights of security holders (Item 3.03), amendments to its charter or bylaws (Item 5.03), and exhibits (Item 9.01). The filing is categorized under Charter/Bylaws Amendments as a material event. No financial performance metrics or period-over-period comparisons were detailed in the provided filing index.

• ·CIK: 0001789192
• ·SIC: 2870 (Agriculture Chemicals)
• ·State of Incorporation: NV
• ·Fiscal Year End: December 31
• ·Mailing/Business Address: 156 Fifth Avenue, 10th Floor, c/o Earthbound LLC, New York, NY 10010-7751

06-04-2026

Nightfood Holdings, Inc. (dba TechForce Robotics, OTCQB:NGTF) announced a Joint Development, Manufacturing, and Licensing Agreement with Oncotelic Therapeutics, Inc. (OTCQB:OTLC) to develop and commercialize AI-Enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. This collaboration combines TechForce's robotics expertise with Oncotelic's AI and biotechnology capabilities, marking TechForce's expansion into biopharma. No financial terms were disclosed.

• ·Filing Date: April 06, 2026
• ·Oncotelic focuses on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications

06-04-2026

On April 3, 2026, La Rosa Holdings Corp. entered into a Settlement Agreement with Reinaldo Zapata and Viviana Figueroa, acquiring their combined 49% membership interests (24.5% each) in majority-owned subsidiary La Rosa Realty Orlando LLC, resulting in LRRO becoming a wholly-owned subsidiary. In exchange, the Company forgave $106,447 allegedly owed by Zapata to LRRO and $152,295 in franchise fee obligations under his personal guaranty, paid $10,000 to Figueroa (with her franchise obligations also forgiven), and dismissed without prejudice the ongoing litigation Case No. 2026-CA-001011-O in Orange County Circuit Court. This transaction resolves disputes, consolidates ownership, and involves minimal cash outlay.

• ·Litigation dismissed: La Rosa Realty Corp., La Rosa Realty Orlando LLC v. Reinaldo Zapata, Viviana Figueroa, Case No. 2026-CA-001011-O, Circuit Court of Orange County, Florida

06-04-2026

On April 1, 2026, Rent the Runway, Inc. entered into the Second Amendment to its Amended and Restated Credit Agreement, originally dated October 28, 2025 and first amended January 28, 2026. The amendment, with lenders and CHS (US) Management LLC as administrative agent, permits the company to capitalize interest in lieu of cash payments until May 3, 2027. This provides liquidity flexibility amid ongoing financing arrangements.

• ·Credit Agreement originally dated October 28, 2025, first amended January 28, 2026
• ·Full text of Second Amendment attached as Exhibit 10.1

06-04-2026

CVC-PE Global Private Equity Fund, LP filed an 8-K announcing the Second Amended and Restated Limited Partnership Agreement dated April 1, 2026, which amends the initial agreement from September 4, 2025, to facilitate the withdrawal of the Initial Unitholder (CVC-PEF TE Blocker (CYM), Ltd.) and the admission of additional limited partners. The agreement outlines governance structure, unit classes (including Class C, D, and G Units), management fees, incentive allocations, and transfer restrictions, with no specific financial performance metrics or period-over-period comparisons disclosed.

• ·Certificate of Limited Partnership filed September 8, 2025
• ·Initial Agreement dated September 4, 2025
• ·Annex A: Form of Investment Advisory Agreement
• ·Annex B: Redemption Program

06-04-2026

Tamboran Resources Corporation and its affiliates amended the Arrangement Agreement dated September 30, 2025, with Falcon Oil & Gas Ltd. to extend the Termination Date for the Plan of Arrangement from a prior date to April 30, 2026, with automatic extension to June 30, 2026 if conditions in Section 5.1(c) remain unsatisfied or OFAC has not issued a required license, provided other closing conditions are met. The amendment was executed on March 31, 2026, pursuant to Section 7.9 of the original agreement, and all other terms remain unchanged. No financial terms or impacts were modified or disclosed.

• ·Amendment filed as EX-2.1 under SEC 8-K Items 1.01 and 9.01 on April 6, 2026
• ·Extension not available to party whose breach caused failure to meet Effective Date
• ·Arrangement Agreement governed by Business Corporations Act (British Columbia)

06-04-2026

Martin Midstream Partners L.P. and Martin Operating Partnership L.P. entered into the Third Amendment to the Fourth Amended and Restated Credit Agreement effective March 31, 2026, reducing aggregate lender Commitments from $130,000,000 to $115,000,000, a decrease of 11.5%. The amendment loosens financial covenants by reducing the minimum Interest Coverage Ratio to 1.65 to 1.00 for fiscal quarters through December 31, 2026 (from prior 2.00 to 1.00 levels), and temporarily increasing the maximum Total Leverage Ratio to 5.50 to 1.00 for the same period (previously up to 4.75 to 1.00). The company certified no material adverse change since December 31, 2024, and no Default or Event of Default exists post-amendment.

• ·Consent fee of 0.05% of each consenting Lender’s Commitment (post-amendment) payable April 1, 2026.
• ·Interest Coverage Ratio minimum steps to 1.75 to 1.00 thereafter; Total Leverage Ratio maximum steps down to 5.00 to 1.00 long-term.
• ·No material adverse change certified since December 31, 2024.

06-04-2026

DHI Group, Inc., along with Dice Inc. and Dice Career Solutions, Inc. as borrowers, entered into a new Credit Agreement dated April 1, 2026, establishing an initial Aggregate Revolving Commitment of $70,000,000 with Bank of America, N.A. as Administrative Agent, Swingline Lender, and L/C Issuer. The agreement includes an Alternative Currency Sublimit of $5,000,000 and is supported by certain subsidiaries as guarantors. No declines or flat performance metrics are present in the filing.

• ·Deal CUSIP Number: 23291LAE3
• ·Published Revolver CUSIP Number: 23291LAF0
• ·Filing Items: 1.01 (Entry into Material Definitive Agreement), 1.02, 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits)

06-04-2026

Greenlane Holdings, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, increasing authorized shares to 1,840,000,000 total, comprising 1,800,000,000 shares of Class A common stock (par value $0.01), 30,000,000 shares of Class B common stock (par value $0.0001), and 10,000,000 shares of preferred stock (par value $0.0001). The amendment implements a 1-for-8 reverse stock split effective 12:01 a.m. Eastern Time on April 6, 2026, with cash payments in lieu of fractional shares based on the prior trading day's Nasdaq closing price. The amendment was stockholder-approved and executed by CEO Jason Hitchcock on April 2, 2026.

• ·Original Certificate of Incorporation filed May 2, 2018.
• ·Reverse stock split applies to Common Stock (Class A and Class B) issued prior to effective time.
• ·No fractional shares issued; cash equivalent calculated using Nasdaq closing price on trading day immediately preceding effective time.